2 active not recruiting, 1 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Active not recruiting 2, Completed 1, Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
Follow Yescarta: new trials by email Literature Review of Yescarta trials Research Report on Yescarta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-11-01 | 2026-11-12 |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine - AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma | Phase 1 | Recruiting | AIDS Malignancy Consortium | 20 | 2025-02-13 | 2026-07-10 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-11-04 |
| Axi-cel in CNS Lymphoma Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel - Lymphoma, Lymphoma Cns | Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 18 | 2020-12-04 | 2026-08-12 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 23 | 2020-12-02 | 2026-06-25 |
Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Non-Hodgkin (2) · HIV Infections (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Follicular (1) · Recurrence (1)
AIDS Malignancy Consortium (1) · Dana-Farber Cancer Institute (1) · Masonic Cancer Center, University of Minnesota (1) · NeoImmuneTech (1) · University of Michigan Rogel Cancer Center (1) · University of Washington (1)
United States (6)
Ajay Gopal (1) · Ariela Noy (1) · Caron Jacobson, MD (1) · John DiPersio, M.D. (1) · Marcus Geer (1) · Veronika Bachanova, MD (1)
UM1CA121947 (1)